Back to News & Events

Weight loss unrelated to decrease in calorie intake after a single dose of a bispecific antibody to FGFR1/Klothoβ in obese subjects

Share this

About this Poster:

BFKB8488A is a humanized, effector-less, bispecific antibody designed to activate the receptor for fibroblast growth factor 21 (FGF21) in adipose tissue, the FGFR1/Klothoß complex. Preclinical studies demonstrated that BFKB8488A largely recapitulates the metabolic actions of recombinant FGF21 in rodents and non-human primates. This Phase 1, first-in-human study was performed with obese but otherwise healthy subjects. The primary objectives were safety, tolerability, and pharmacokinetics. Additionally, insulin, glucose, lipids, and other metabolic markers were measured.

Your development journey
starts with a conversation.

ProSciento
Privacy Overview

More information about our Privacy Policy can be found here.